Dasatinib

Generic Name
Dasatinib
Brand Names
Sprycel
Drug Type
Small Molecule
Chemical Formula
C22H26ClN7O2S
CAS Number
302962-49-8
Unique Ingredient Identifier
X78UG0A0RN
Background

Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...

Indication

Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...

Associated Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

Phase 1
Withdrawn
Conditions
Relapsed AML
T(8;21)
C-KIT Mutation
Interventions
Drug: Dasatinib
First Posted Date
2018-06-18
Last Posted Date
2020-03-23
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Registration Number
NCT03560908
Locations
🇨🇳

HBDH, Tianjin, Tianjin, China

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

First Posted Date
2018-05-04
Last Posted Date
2024-12-04
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
40
Registration Number
NCT03516279
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States

🇺🇸

Bethesda North Hospital, Cincinnati, Ohio, United States

and more 287 locations

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

First Posted Date
2018-05-03
Last Posted Date
2020-09-01
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
12
Registration Number
NCT03515200
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

First Posted Date
2018-01-30
Last Posted Date
2018-10-25
Lead Sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Registration Number
NCT03414450
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

First Posted Date
2017-11-24
Last Posted Date
2022-10-05
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
3
Registration Number
NCT03352427
Locations
🇺🇸

University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

First Posted Date
2017-09-29
Last Posted Date
2024-11-12
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
720
Registration Number
NCT03297606
Locations
🇨🇦

Verspeeten Family Cancer Centre, London, Ontario, Canada

🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

🇨🇦

BCCA - Kelowna, Kelowna, British Columbia, Canada

and more 7 locations

KISS Study: Kinase Inhibition With Sprycel Start up

Phase 2
Active, not recruiting
Conditions
Chronic Myeloid Leukemia
Interventions
Drug: Dasatinib
Drug: Imatinib
First Posted Date
2017-06-20
Last Posted Date
2023-11-29
Lead Sponsor
University of Auckland, New Zealand
Target Recruit Count
91
Registration Number
NCT03193281
Locations
🇳🇿

Dunedin Hospital, Dunedin, New Zealand

🇳🇿

Auckland City Hospital, Auckland, New Zealand

🇳🇿

Taranaki Base Hospital, New Plymouth, New Zealand

and more 6 locations

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Not Applicable
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Dasatinib
First Posted Date
2017-06-02
Last Posted Date
2022-08-03
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
132
Registration Number
NCT03173612
Locations
🇨🇳

InstituteHBDH, Tianjin, Tianjin, China

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

First Posted Date
2017-04-18
Last Posted Date
2024-11-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
790
Registration Number
NCT03117751
Locations
🇺🇸

Children's Hospital of Michigan, Detroit, Michigan, United States

🇺🇸

St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States

🇦🇺

The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

and more 5 locations

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

First Posted Date
2017-02-03
Last Posted Date
2022-04-14
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
14
Registration Number
NCT03041701
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy